Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications

Qiu, Jiangdong; Ye, Gang; Feng, Mengyu; Zheng, Suli; Cao, Zhe; You, Lei; Zheng, Lianfang; Zhang, Taiping; Zhao, Yupei

doi:10.1186/s12943-017-0755-z

Cited by 58 publications

(66 citation statements)

References 118 publications

(133 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rabinowits et al reported that in lung adenocarcinoma, circulating total miRNAs can be used as a screening tool because they observed a significant difference between patients and healthy controls ( 79 ). Several miRNAs (miR-17-5p, miR-21, miR-550, miR-10b) were characterized from exosomes isolated from peripheral blood of pancreatic cancer patients, suggesting the use as early biomarkers ( 80 ). Similarly, miR-373 was significantly elevated in the serum of TNBC patients as compared to control subjects ( 81 ).…”

Section: Exosomes As Diagnostic Agents or In Cancer Therapeuticsmentioning

confidence: 99%

The Origin and Functions of Exosomes in Cancer

2018

View full text Add to dashboard Cite

Exosomes are nanovesicles having a maximum size of 150 nm and is a newly emerging focus in various fields of research. Its role in cargo trafficking along with its differential expression is associated with the disrupted homeostasis and provides an opportunity to defend against different diseases like cancer. Furthermore, exosomes are rich in cargos, which contain proteins and nucleic acids that directly reflect the metabolic state of the cells from which it originates. This review summarizes recent studies on tumor-derived exosomes with an overview about biogenesis, their functions and potential of using as diagnostic and prognostic markers. We also discussed the current challenges and microfluidic-based detection approaches that might improve the detection of exosomes in different settings. More intricate studies of the molecular mechanisms in angiogenesis, pre-metastatic niche formation, and metastasis can give more promising insights and novel strategies in oncotherapeutics.

show abstract

Section: Exosomes As Diagnostic Agents or In Cancer Therapeuticsmentioning

confidence: 99%

The Origin and Functions of Exosomes in Cancer

2018

View full text Add to dashboard Cite

show abstract

“…MDSCs can also inhibit the migration of T cells to peripheral lymph nodes by decreasing the expression of CD62L on the surface of immature T cells to suppress the activation of T cells . A panoply of cytokines produced by tumor cells like TGF‐β, IL‐6, IL‐10, and GM‐CSF can contribute to the production of ROS in MDSCs that can increase FasL expression but decrease Bcl2 expression, leading to the apoptosis of activated T cells . Meanwhile, ROS can inhibit hematopoietic progenitor cells (HPCs) differentiating into DCs …”

Section: Main Functional Characteristics Of Mdscsmentioning

confidence: 99%

Myeloid‐derived suppressor cells: Roles in the tumor microenvironment and tumor radiotherapy

Yin

Wang

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

Cancer progression is closely related to the tumor microenvironment in which the tumor exists, including surrounding blood vessels, immune cells, fibroblasts, bone marrow-derived inflammatory cells, signaling molecules and the extracellular matrix. Tumors can influence the microenvironment by releasing extracellular signals, promoting tumor angiogenesis and inducing peripheral immune tolerance, while the immune cells in the microenvironment can impact the growth and evolution of cancerous cells. One of major cell components in the tumor microenvironment is myeloid-derived suppressor cells (MDSCs), which promote tumor growth and metastasis directly or indirectly by recognizing other immune cells, producing cytokines and exerting their immunosuppression functions. MDSCs have emerged as major regulators of immune responses in cancer and key targets for treating cancer. There are many limitations and side-effect in approaches of conventional cancer therapy, including radiotherapy. It has grown up to be a burgeoning field that a combination of radiotherapy and immunotherapy applied to cancer therapy. Therefore, it is fundamental to explore the immune mechanism in the process of cancer treatment. Here, we reviewed the recent progress of MDSCs in roles of the tumor microenvironment and tumor radiotherapy.

show abstract

“…Efforts focused on targeting PC have been disappointing (7,36), so the standard of care for PC continues to be chemotherapy. However, chemoresistance is a major challenge in the treatment of PC (14,15,17,18). The efficacy of GEM monotherapy for PC is limited by emerging drug resistance, which can be intrinsic or acquired after multiple treatment cycles.…”

Section: Discussionmentioning

confidence: 99%

“…However, chemotherapy resistance remains a key challenge in PC treatment (14,15). In addition to cancer cells, the tumor microenvironment and pharmacokinetics contribute to clinical chemotherapy failure and apparent drug resistance (16)(17)(18).…”

Section: Introductionmentioning

confidence: 99%

Pharmacometabolomics Identifies 3-Hydroxyadipic Acid, d-Galactose, Lysophosphatidylcholine (P-16:0), and Tetradecenoyl-l-Carnitine as Potential Predictive Indicators of Gemcitabine Efficacy in Pancreatic Cancer Patients

Zhang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Gemcitabine (GEM)-based chemotherapy is the standard regimen for the treatment of pancreatic cancer (PC). However, chemoresistance is a major challenge in PC treatment. Reliable biomarkers are urgently needed to predict the response to GEM-based therapies. GEM-sensitive (GEM-S) and GEM-resistant (GEM-R) pancreatic carcinoma xenograft models were established, and GEM monotherapy and GEM plus nanoparticle albumin-bound paclitaxel (nab-PTX) doublet therapy were administered to GEM-S/R tumor-bearing mice. Metabolomic mass spectrometry (MS) analysis of serum, liver, and tumor samples was performed using an ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometer. The results showed that both GEM monotherapy and combination therapy significantly inhibited the tumor growth in GEMS subgroup. However, in the GEM-R subgroup, tumor growth was not significantly inhibited by GEM monotherapy, but was significantly suppressed by GEM combination therapy. Metabolic profiling analysis by hierarchical cluster analysis and partial least squares discriminant analysis showed that the differences in metabolites were most significant in serum of three types of samples in the GEM-S/R subgroups, regardless of the administration of GEM monotherapy or combination therapy. The differential metabolite analysis of serum samples revealed 38 and 26 differential metabolites between the GEM-R and GEMS subgroups treated with GEM monotherapy or combination therapy, and four common discriminating metabolites were investigated: 3-hydroxyadipic acid, D-galactose, lysophosphatidylcholine (LysoPC) (P-16:0), and tetradecenoyl-L-carnitine. The relative amounts of the four metabolites changed significantly and consistently after GEM monotherapy or combination therapy. The levels of these four metabolites Wu et al.

show abstract

Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications

Cited by 58 publications

References 118 publications

The Origin and Functions of Exosomes in Cancer

The Origin and Functions of Exosomes in Cancer

Myeloid‐derived suppressor cells: Roles in the tumor microenvironment and tumor radiotherapy

Pharmacometabolomics Identifies 3-Hydroxyadipic Acid, d-Galactose, Lysophosphatidylcholine (P-16:0), and Tetradecenoyl-l-Carnitine as Potential Predictive Indicators of Gemcitabine Efficacy in Pancreatic Cancer Patients

Contact Info

Product

Resources

About